With better risk stratification, clinicians may be able to optimize medical management of patients with chronic HBV who don’t ...

Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the effectiveness of peptide-based cancer vaccines, ...

Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could ...

Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free ...

(RTTNews) - Coherus BioSciences, Inc. (CHRS), Wednesday announced final data from its Phase 2 study evaluating casdozokitug in combination with atezolizumab and bevacizumab in patients with ...

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

Researchers at Mount Sinai have achieved a significant breakthrough in treating hepatocellular carcinoma (HCC), the most ...

The quantitative effects of alcohol consumption on cirrhosis and hepatocellular carcinoma (HCC) in hepatitis B virus (HBV) infection are unknown.

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”) ...

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...